ADHERENCE, QUALITY OF LIFE AND PATIENT SATISFACTION WITH DALFAMPRIDINE IN CLINICAL PRACTICE

B. Marzal Alfaró1, M.L. Martin-Barbero1, A. Ribed1, J.L. Revuelta1, M. Tovar-Pozo1, A. de Lorenzo-Pinto1, C. Ortega Navarro2, A. Herranz-Alonso2, M. Sanjurjo-Saez2

Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IIsgM). Madrid, España

OBJECTIVES

Background: Mobility impairment is a major concern for many patients with multiple sclerosis (MS). Dalfampridine improves walking speed and consequently it may improve quality of life (QOL), but adherence is a key factor to assure it.

OBJECTIVE: To assess adherence and degree of satisfaction with dalfampridine in our MS patients.

METHODS

• Design: observational, prospective study from May 2014 to March 2015.
• Inclusion criteria: MS patients on dalfampridine treatment for at least 6 months.
• Variables: demographic information, disease duration, type of MS, Expanded Disability Status Scale (EDSS).
• Endpoints: - Morisky-Green adherence questionnaire
  - General satisfaction visual analogue scale (VAS)
  - Items related to QOL: improved with fampridine treatment: mobility, self-care, usual activities, pain/discomfort, anxiety/depression.

RESULTS

• Population: 30 patients, 14 women (46.7%).
• Mean age: 39 years (SD=9.7).
• Mean duration of MS: 13.7 years (SD=6.4).
• Mean EDSS before treatment initiation: 5.8 (SD=0.9).
• Walking aids needed by 24 patients (80%)

CONCLUSIONS

• Adherence to dalfampridine treatment was suboptimal and was reinforced by hospital pharmacist in pharmaceutical care visits.
• According to satisfaction questionnaires, dalfampridine benefited patients in several aspects of QOL, not only mobility.
• Dalfampridine effectiveness should be judged including patients’ self-report in addition to the information provided by MS-specific assessment scales.